Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease

Yılmaz, Yusuf; Kurt, Ramazan; Gürdal, Ahmet; Alahdab, Yeşim Özen; Yönal, Oya; Şenateş, Ebubekir; Polat, Nihat; Eren, Fatih; İmeryüz, Neşe; Oflaz, Hüseyin

doi:10.1016/j.atherosclerosis.2011.03.026

Cited by 48 publications

(38 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study in CHC patients, serum chemerin concentration was higher when compared to controls [32]. Some other studies in patients with histologically confirmed NAFLD found higher circulating chemerin levels in NAFLD patients than in controls [19,20,21]. On the other hand, when chemerin serum levels were compared between patient with NASH and simple steatosis the results were not so explicit.…”

Section: Discussionmentioning

confidence: 67%

“…Chemerin levels in humans are associated with body mass index (BMI), lipids concentration, blood pressure, and insulin sensitivity [11,17,18]. Several studies indicated altered chemerin levels or hepatic chemerin expression in chronic liver diseases of different origin, including NAFLD and chronic hepatitis C (CHC) [5,19,20,21,22,23,24,25]. Chemerin acts by binding the G protein-coupled receptor, chemokine receptor-like 1 (CMKLR1) (also known as chemerin receptor 23 (ChemR23)) [7,26], expressed by a variety of cells [26,27,28,29].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease

Kajor¹,

Kukla²,

Waluga³

et al. 2017

pjp

View full text Add to dashboard Cite

The aim of this study was to investigate hepatic chemerin mRNA, serum chemerin concentration, and immunohistochemical staining for chemerin and and chemokine receptor-like 1 (CMKLR1) in hepatic tissue in 56 morbidly obese women with nonalcoholic fatty liver disease (NAFLD) and to search for a relationship with metabolic and histopathological features. Chemerin mRNA was assessed by quantitative real-time PCR, chemerin, and CMKLR1 immunohistochemical expression with specific antibodies, while serum chemerin concentration was assessed with commercially available enzyme-linked immunosorbent assays. Serum chemerin concentration reached 874.1 ±234.6 ng/ml. There was no difference in serum chemerin levels between patients with BMI < 40 kg/m 2 and ≥ 40 kg/m 2 . Serum chemerin concentration tended to be higher in patients with hepatocyte ballooning, greater extent of steatosis, and definite nonalcoholic steatohepatitis (NASH). Liver chemerin mRNA was observed in all included patients and was markedly, but insignificantly, higher in those with BMI ≥ 40 kg/ m 2 , hepatocyte ballooning, greater extent of steatosis, and definite NASH. Hepatic chemerin mRNA might be a predictor of hepatic steatosis, hepatocyte ballooning, and NAFLD activity score (NAS) but seemed not to be a primary driver regulating liver necroinflammatory activity and fibrosis. The lack of association between serum chemerin and hepatic chemerin mRNA may suggest that adipose tissue but not the liver is the main source of chemerin in morbidly obese women.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Introductionmentioning

confidence: 99%

Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease

Kajor¹,

Kukla²,

Waluga³

et al. 2017

pjp

View full text Add to dashboard Cite

show abstract

“…MCD diet strongly lowers body weight and when adjusted to body weight serum chemerin is even increased [13]. Yilmaz et al analyzed serum of 54 patients with biopsy-proven NAFLD and 56 age-and sex-matched controls and found increased chemerin in NAFLD [41]. This group also analyzed serum of 99 patients with biopsy-proven NAFLD and 75 control subjects and found elevated serum chemerin in the first cohort [42].…”

Section: Serum Chemerin In Nafldmentioning

confidence: 99%

Chemerin in Liver Diseases

2014

Endocrinol Metab Synd

View full text Add to dashboard Cite

Chemerin is a chemoattractant protein and moreover has a role in adipogenesis, angiogenesis and glucose homeostasis. Chemerin is primarily synthesized and secreted by adipocytes and hepatocytes. Chemerin receptors chemokine-like receptor 1 (CMKLR1), G-protein coupled receptor 1 (GPR1) and CC-motif chemokine receptorlike 2 (CCRL2) are all expressed in the liver suggesting that chemerin may be relevant in liver physiology and pathophysiology. Non-alcoholic fatty liver disease (NAFLD) is associated with obesity and is the most common cause of chronic liver injury. NAFLD and chronic hepatitis C virus infection are risk factors for hepatocellular carcinoma. Hepatic and serum chemerin have been analyzed in human and rodent NAFLD, in patients with chronic hepatitis C and patients with hepatocellular carcinoma. Chemerin, GPR1 and CMKLR1 deficient mice have been used to elucidate the role of these proteins in body weight gain and glucose homeostasis. The regulation of chemerin and CMKLR1 by adipokines, hormones and cytokines relevant in liver diseases has been studied in hepatocytes. The data published so far are briefly summarized herein. Current experimental findings do not provide evidence for a crucial role of chemerin in chronic liver diseases and further research is needed to evaluate a possible protective function of this protein in hepatocellular carcinoma.

show abstract

“…Visceral adipose tissue thickness is associated with hip and thigh circumference or subcutaneous fat thickness (15). EFT was significantly higher in patients with nonalcoholic fatty liver disease (16). Pathological investigations revealed EFT and the adventitia of coronary arteries or myocardium to be contiguous, with no intervening structures (10).…”

Section: Introductionmentioning

confidence: 99%

Correlation of echocardiographic epicardial fat thickness with severity of coronary artery disease-an observational study

Shemirani

Khoshavi²

2012

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Objective: Epicardial fat is an indirect contact with coronary arteries. There are some studies about the relationship between this fat and metabolic syndrome and it has considered as an indicator of cardiovascular risk. Several studies have addressed the association between epicardial fat thickness (EFT) and coronary artery disease (CAD) with conflicting results. The aim of our study was to evaluate the hypothesis that echocardiographic EFT thickness could be a marker severe CAD. Methods: Overall, 315 cases who underwent coronary angiography were classified in two groups: Normal and CAD. Measurement of EFT was done with echocardiography. The difference between mean EFT in two groups was analyzed. Califf scoring considered for severity of CAD. Then the relationship between EFT and age, sex, body mass index (BMI), serum lipids and severity of CAD was evaluated. The obtained data were compared by using ANCOVA test, Pearson and Spearman's partial correlation analyses. Results: The EFT in CAD group was significantly higher than in normal group (5.4±1.9 mm vs 4.4±1.8mm, p=0.0001). EFT had a positive relationship with Califf scoring of diseased coronary arteries (r=0.158 p=0.04), low-density lipoprotein cholesterol (p=0.04), female gender (p=0.02), BMI (p=0.001) and serum triglyceride levels (p=0.04).

show abstract

Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease

Cited by 48 publications

References 29 publications

Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease

Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease

Chemerin in Liver Diseases

Correlation of echocardiographic epicardial fat thickness with severity of coronary artery disease-an observational study

Contact Info

Product

Resources

About